{"nctId":"NCT05297565","briefTitle":"A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection","startDateStruct":{"date":"2022-08-02","type":"ACTUAL"},"conditions":["Melanoma"],"count":14,"armGroups":[{"label":"Arm A: Subcutaneous Nivolumab","type":"EXPERIMENTAL","interventionNames":["Biological: Nivolumab/rHuPH20"]},{"label":"Arm B: Intravenous Nivolumab","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Nivolumab"]}],"interventions":[{"name":"Nivolumab/rHuPH20","otherNames":["BMS-986298"]},{"name":"Nivolumab","otherNames":["BMS-936558","Opdivo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Stage IIIA/B/C/D or Stage IV melanoma and have histologically confirmed melanoma that is completely surgically resected (free of disease) with negative margins\n* Complete resection performed within 12 weeks prior to randomization or treatment assignment\n* Eastern Cooperative Oncology Group (ECOG) performance status of â‰¤ 1\n\nExclusion Criteria:\n\n* History of uveal or mucosal melanoma\n* Untreated/unresected CNS metastases or leptomeningeal metastases\n* Active, known or suspected autoimmune disease\n* Serious or uncontrolled medical disorder 4 weeks prior to screening\n* Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to randomization or treatment assignment. Participants with history of prior early stage basal/squamous cell skin cancer or non-invasive or in situ cancers that have undergone definitive treatment at any time are eligible\n* Prior immunotherapy treatments for any prior malignancies are not permitted\n\nOther protocol-defined inclusion/exclusion criteria apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Adverse Events","description":"An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.\n\nAn AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Serious Adverse Events","description":"A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose:\n\n* Results in death.\n* Is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe).\n* Requires inpatient hospitalization or causes prolongation of existing hospitalization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Treatment Related Adverse Events","description":"An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment.\n\nAn AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom or disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Treatment Related Serious Adverse Events","description":"A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose:\n\n* Results in death.\n* Is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe).\n* Requires inpatient hospitalization or causes prolongation of existing hospitalization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":6},"commonTop":["Asthenia","Diarrhoea","Cough","Pruritus","Hypertension"]}}}